RBC Capital Reiterates Outperform on Ascendis Pharma, Maintains $290 Price Target
Benzinga Newsdesk 11 hours ago
Analyst RatingsNewsReiterationPrice Target
RBC Capital analyst Luca Issi reiterates Ascendis Pharma (NASDAQ:ASND) with a Outperform and maintains $290 price target.
RBC Capital analyst Luca Issi reiterates Ascendis Pharma (NASDAQ:ASND) with a Outperform and maintains $290 price target.